DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NCT04042701)
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)
🩺 Plain-English Summary (8th-Grade Level)
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
Who can join: Review the eligibility criteria below.
Location: Univ. of Cali. San Francisco Medical Center — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- Univ. of Cali. San Francisco Medical Center — San Francisco, California
- Yale Cancer Center — New Haven, Connecticut
- Cancer Specialists of North Florida (Cbo) — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Moffit Cancer Center — Tampa, Florida
- Center for Cancer & Blood Disorders — Bethesda, Maryland
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts
- Siteman Cancer Center-Washington University — St Louis, Missouri
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Hope Cancer Center of East Texas — Tyler, Texas
- Institut Bergonie — Bordeaux,
- Centre Hospitalier Intercommunal de Créteil — Créteil,
- CHUTimone — Marseille,
- Institut PAOLI-CALMETTES — Marsielle,
- CHU de Poitiers — Poitiers,
- Univ. du Cancer de Toulouse — Toulouse,
- Institut Gustave Roussy — Villejuif,
- Hospital Teresa Herrera (C.H.U.A.C) — A Coruña,
- Inst. Oncologico Baselga Hospital Quiron — Barcelona,
- Hospital de la Santa Creu i de Sant Pau — Barcelona,
- Hopital Universitario Insular de Gran Canaria — Las Palmas de Gran Canaria,
- Hospital General Univ. Gregorio Marañon — Madrid,
- MD Anderson Cancer Center — Madrid,
- Hospital Universitario 12 de Octubre — Madrid,
- Hospital Universitario Virgen Macarena — Seville,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.